These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 25182065)

  • 1. Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
    Pasipanodya JG; Srivastava S; Gumbo T
    J Antimicrob Chemother; 2015 Jan; 70(1):320-1. PubMed ID: 25182065
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study--authors' response.
    Prahl JB; Johansen IS; Cohen AS; Frimodt-Møller N; Andersen ÅB
    J Antimicrob Chemother; 2015 Jan; 70(1):321-2. PubMed ID: 25246439
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
    Prahl JB; Johansen IS; Cohen AS; Frimodt-Møller N; Andersen ÅB
    J Antimicrob Chemother; 2014 Oct; 69(10):2841-7. PubMed ID: 25140577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-tuberculosis drugs].
    Doi N
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():367-74. PubMed ID: 17455647
    [No Abstract]   [Full Text] [Related]  

  • 5. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.
    Kumar AKH; Chandrasekaran V; Kumar AK; Kawaskar M; Lavanya J; Swaminathan S; Ramachandran G
    Indian J Med Res; 2017 Apr; 145(4):530-535. PubMed ID: 28862186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.
    Jia L; Tomaszewski JE; Hanrahan C; Coward L; Noker P; Gorman G; Nikonenko B; Protopopova M
    Br J Pharmacol; 2005 Jan; 144(1):80-7. PubMed ID: 15644871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
    Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
    Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
    Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
    Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
    Dutt M; Khuller GK
    Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    Saktiawati AM; Sturkenboom MG; Stienstra Y; Subronto YW; Sumardi ; Kosterink JG; van der Werf TS; Alffenaar JW
    J Antimicrob Chemother; 2016 Mar; 71(3):703-10. PubMed ID: 26661397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
    Peloquin CA; Velásquez GE; Lecca L; Calderón RI; Coit J; Milstein M; Osso E; Jimenez J; Tintaya K; Sanchez Garavito E; Vargas Vasquez D; Mitnick CD; Davies G
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the World Health Organization.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S282-3. PubMed ID: 10593704
    [No Abstract]   [Full Text] [Related]  

  • 14. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action.
    Rivers EC; Mancera RL
    Drug Discov Today; 2008 Dec; 13(23-24):1090-8. PubMed ID: 18840542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
    Jayaram R; Shandil RK; Gaonkar S; Kaur P; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Kantharaj E; Balasubramanian V
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2951-7. PubMed ID: 15273105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs.
    Baietto L; Calcagno A; Motta I; Baruffi K; Poretti V; Di Perri G; Bonora S; D'Avolio A
    J Antimicrob Chemother; 2015 Sep; 70(9):2572-5. PubMed ID: 26066583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Administration of antituberculous drugs to subjects with basic diseases. 1. Chemotherapy of tuberculosis in patients with impaired renal function].
    Usuta Y
    Kekkaku; 1987 Dec; 62(12):664-7. PubMed ID: 3448351
    [No Abstract]   [Full Text] [Related]  

  • 20. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin.
    Magis-Escurra C; Later-Nijland HM; Alffenaar JW; Broeders J; Burger DM; van Crevel R; Boeree MJ; Donders AR; van Altena R; van der Werf TS; Aarnoutse RE
    Int J Antimicrob Agents; 2014 Sep; 44(3):229-34. PubMed ID: 24985091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.